(0.33%) 5 116.74 points
(0.33%) 38 367 points
(0.38%) 15 988 points
(-0.98%) $83.03
(5.51%) $2.03
(0.33%) $2 354.90
(0.46%) $27.66
(4.06%) $959.50
(-0.26%) $0.932
(-0.42%) $10.98
(-0.56%) $0.796
(1.66%) $93.40
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.62%
@ $36.11
発行日: 15 2月 2024 @ 03:49
リターン: 3.97%
前回のシグナル: 2月 14 - 02:40
前回のシグナル:
リターン: 0.46 %
Live Chart Being Loaded With Signals
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases...
Stats | |
---|---|
本日の出来高 | 106 626 |
平均出来高 | 937 108 |
時価総額 | 2.47B |
EPS | $0 ( 2024-02-27 ) |
次の収益日 | ( $-0.670 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -12.86 |
ATR14 | $0.0390 (0.10%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-13 | Jimenez Freddy A. | Buy | 20 000 | Common Stock |
2024-02-13 | Jimenez Freddy A. | Buy | 4 166 | Common Stock |
2024-02-13 | Jimenez Freddy A. | Sell | 4 166 | Incentive Stock Option (Right to Buy) |
2024-02-13 | Jimenez Freddy A. | Sell | 20 000 | Incentive Stock Option (Right to Buy) |
2024-01-02 | Martin Samuel Bates | Buy | 10 750 | Common Stock |
INSIDER POWER |
---|
75.21 |
Last 97 transactions |
Buy: 2 900 849 | Sell: 507 801 |
ボリューム 相関
Celldex Therapeutics Inc 相関
10 最も負の相関 | |
---|---|
CHMA | -0.906 |
VTIP | -0.906 |
DSPG | -0.895 |
SUMO | -0.893 |
SOPH | -0.887 |
SMED | -0.882 |
OSMT | -0.878 |
NVCN | -0.876 |
MNTV | -0.876 |
DVCR | -0.872 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Celldex Therapeutics Inc 相関 - 通貨/商品
Celldex Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $6.88M |
総利益: | $3.88M (56.30 %) |
EPS: | $-2.92 |
FY | 2023 |
収益: | $6.88M |
総利益: | $3.88M (56.30 %) |
EPS: | $-2.92 |
FY | 2022 |
収益: | $2.36M |
総利益: | $957 000 (40.60 %) |
EPS: | $-2.62 |
FY | 2021 |
収益: | $4.65M |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.640 |
Financial Reports:
No articles found.
Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。